Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations
Date
2014
Authors
Scheffer, I.
Heron, S.
Regan, B.
Mandelstam, S.
Crompton, D.
Hodgson, B.
Licchetta, L.
Provini, F.
Bisulli, F.
Vadlamudi, L.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Annals of Neurology, 2014; 75(5):782-787
Statement of Responsibility
Ingrid E. Scheffer, Sarah E. Heron, Brigid M. Regan, Simone Mandelstam, Douglas E. Crompton, Bree L. Hodgson, Laura Licchetta, Francesca Bisulli, Lata Vadlamudi, Jozef Gecz, Alan Connelly, Paolo Tinuper, Michael G. Ricos, Samuel F. Berkovic and Leanne M. Dibbens
Conference Name
Abstract
We recently identified DEPDC5 as the gene for familial focal epilepsy with variable foci and found mutations in >10% of small families with nonlesional focal epilepsy. Here we show that DEPDC5 mutations are associated with both lesional and nonlesional epilepsies, even within the same family. DEPDC5-associated malformations include bottom-of-the-sulcus dysplasia (3 members from 2 families), and focal band heterotopia (1 individual). DEPDC5 negatively regulates the mammalian target of rapamycin (mTOR) pathway, which plays a key role in cell growth. The clinicoradiological phenotypes associated with DEPDC5 mutations share features with the archetypal mTORopathy, tuberous sclerosis, raising the possibility of therapies targeted to this pathway.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2014 American Neurological Association